Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT01570010
Other study ID # CRC-NORDIET study
Secondary ID 2011/836
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date March 1, 2012
Est. completion date December 31, 2040

Study information

Verified date March 2022
Source University of Oslo
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The current study is designed to gain a better understanding of the role of a healthy diet aimed at dampening inflammation and oxidative stress on long-term disease outcomes and survival in colorectal cancer patients. Since previous research on the role of diet for colorectal cancer survivors is limited, the study may be of great importance for this cancer population.


Description:

Men and women aged 50-80 years diagnosed with primary invasive colorectal cancer (Stage I-III) are invited to this randomized controlled, parallel two-arm trial 2-9 months after curative surgery. The intervention group (n = 250) receives an intensive dietary intervention lasting for 12 months and a subsequent maintenance intervention for 14 years. The control group (n = 250) receives no dietary intervention other than standard clinical care. Both groups are offered equal general advice of physical activity. Patients are followed-up at 6 months and 1, 3, 5, 7, 10 and 15 years after baseline. The study center is located at the Department of Nutrition, University of Oslo, and patients are recruited from two hospitals within the South-Eastern Norway Regional Health Authority. Primary outcomes are disease-free survival and overall survival. Secondary outcomes are time to recurrence, cardiovascular disease-free survival, compliance to the dietary recommendations and the effects of the intervention on new comorbidities, intermediate biomarkers, nutrition status, physical activity, physical function and quality of life.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 503
Est. completion date December 31, 2040
Est. primary completion date December 31, 2034
Accepts healthy volunteers No
Gender All
Age group 50 Years to 80 Years
Eligibility Inclusion Criteria: - colorectal cancer (ICD10 C18-20) TNM Stage I-III Exclusion Criteria: - TNM stage 0 or IV

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Norwegian food based dietary guidelines
several means will be applied to guide participarts to cohere to the dietary guidelines including access to clinical nutritionists, free food, food discounts, cooking courses, cookbook/recipies, study website, organized physical activity, etc

Locations

Country Name City State
Norway Akershus University Hospital Lørenskog
Norway Oslo University Hospital Oslo
Norway University of Oslo Oslo

Sponsors (6)

Lead Sponsor Collaborator
University of Oslo Finnish Institute for Health and Welfare, Norwegian Cancer Society, Oslo University Hospital, The Research Council of Norway, University Hospital, Akershus

Country where clinical trial is conducted

Norway, 

References & Publications (5)

Alavi DH, Henriksen HB, Lauritzen PM, Kværner AS, Sakinis T, Langleite TM, Henriksen C, Bøhn SK, Paur I, Wiedswang G, Smeland S, Blomhoff R. Quantification of adipose tissues by Dual-Energy X-Ray Absorptiometry and Computed Tomography in colorectal cancer — View Citation

Henriksen C, Paur I, Pedersen A, Kværner AS, Ræder H, Henriksen HB, Bøhn SK, Wiedswang G, Blomhoff R. Agreement between GLIM and PG-SGA for diagnosis of malnutrition depends on the screening tool used in GLIM. Clin Nutr. 2022 Feb;41(2):329-336. doi: 10.10 — View Citation

Henriksen HB, Berntsen S, Paur I, Zucknick M, Skjetne AJ, Bøhn SK, Henriksen C, Smeland S, Carlsen MH, Blomhoff R. Validation of two short questionnaires assessing physical activity in colorectal cancer patients. BMC Sports Sci Med Rehabil. 2018 May 29;10 — View Citation

Henriksen HB, Carlsen MH, Paur I, Berntsen S, Bøhn SK, Skjetne AJ, Kværner AS, Henriksen C, Andersen LF, Smeland S, Blomhoff R. Relative validity of a short food frequency questionnaire assessing adherence to the Norwegian dietary guidelines among colorec — View Citation

Henriksen HB, Ræder H, Bøhn SK, Paur I, Kværner AS, Billington SÅ, Eriksen MT, Wiedsvang G, Erlund I, Færden A, Veierød MB, Zucknick M, Smeland S, Blomhoff R. The Norwegian dietary guidelines and colorectal cancer survival (CRC-NORDIET) study: a food-base — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Disease-free survival Disease-free survival (DFS) (events are defined as detection of local recurrence or metastasis or any second cancer or death from any cause) 5, 10 and 15 years
Primary Overall survival Overall survival (OS) (event is defined as death from any cause) 10, 15 years
Secondary Time to recurrence Events are defined as detection of local recurrence or metastasis up to 15 years
Secondary CVD -free survival Events of CVD (ICD-10; chapter I) or death from any cause up to 15 years
Secondary CRC-specific survival death due to CRC up to 15 years
Secondary Total cancer-specific survival death due to CRC or any other cancer up to 15 years
Secondary Inflammatory disease-specific survival death due to inflammatory disease up to 15 years
Secondary Cardiovascular (CVD)-specific survival death due to CVD up to 15 years
Secondary New morbidity of other diet-related chronic diseases e.g. ischemic coronary heart disease, cerebrovascular disease, thromboembolic disease, type 2 diabetes, obesity, hypertension and chronic obstructive pulmonary disease up to 15 years
Secondary Dietary intake and nutritional status Questionnaires, food records, clinical consultation up to 15 years
Secondary Physical activity and function Questionnaires, arm band, physical tests up to 15 years
Secondary Nutrition biomarkers e.g., carotenoids, fatty acids, 25-hydroxy vitamin D etc up to 15 years
Secondary Body composition DXA, CT, BIA up to 15 years
Secondary Anthropometric measures eg weight, waist and hip circumference up to 15 years
Secondary Biomarkers for inflammation and oxidative stress e.g. isoprostanes, cytokines up to 15 years
Secondary Transcription- and epigenetic profiles sequencing and arrays up to 15 years
Secondary Biomarkers for cardiovascular disease, metabolic syndrome, type 2-diabetes, thromboembolic disease and cancer e.g. blood pressure, total/LDLcholesterol, HbA1c, CRP, IL-6, IL-10, TNFa up to 15 years
Secondary Health related quality of life and fatigue Questionnaires up to 15 years
See also
  Status Clinical Trial Phase
Recruiting NCT05400122 - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Phase 1
Active, not recruiting NCT05551052 - CRC Detection Reliable Assessment With Blood
Completed NCT00098787 - Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT05425940 - Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer Phase 3
Suspended NCT04595604 - Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery. N/A
Completed NCT03414125 - Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening N/A
Completed NCT02963831 - A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Phase 1/Phase 2
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Terminated NCT01847599 - Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib N/A
Completed NCT05799976 - Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure N/A
Recruiting NCT03874026 - Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT03181334 - The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation N/A
Completed NCT03167125 - Participatory Research to Advance Colon Cancer Prevention N/A
Recruiting NCT04258137 - Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study N/A
Recruiting NCT05568420 - A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
Recruiting NCT02972541 - Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer N/A
Completed NCT02876224 - Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors Phase 1
Completed NCT01943500 - Collection of Blood Specimens for Circulating Tumor Cell Analysis N/A